These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 36513818)

  • 81. Prognostic models integrating quantitative parameters from baseline and interim positron emission computed tomography in patients with diffuse large B-cell lymphoma: post-hoc analysis from the SAKK38/07 clinical trial.
    Zucca E; Cascione L; Ruberto T; Facchinelli D; Schär S; Hayoz S; Dirnhofer S; Giovanella L; Bargetzi M; Mamot C; Ceriani L
    Hematol Oncol; 2020 Dec; 38(5):715-725. PubMed ID: 32947651
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Prognostic Value of Anemia and C-Reactive Protein Levels in Diffuse Large B-Cell Lymphoma.
    Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
    Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):671-9. PubMed ID: 26361646
    [TBL] [Abstract][Full Text] [Related]  

  • 83. The immune-metabolic-prognostic index and clinical outcomes in patients with non-small cell lung carcinoma under checkpoint inhibitors.
    Castello A; Toschi L; Rossi S; Mazziotti E; Lopci E
    J Cancer Res Clin Oncol; 2020 May; 146(5):1235-1243. PubMed ID: 32048008
    [TBL] [Abstract][Full Text] [Related]  

  • 84. [Prognostic significance of NCCN-International Prognostic Index (NCCN-IPI) for patients with peripheral T-cell lymphoma treated with CHOP-based chemotherapy].
    Zhang MC; Xu PP; Zhong HJ; Zhao X; Zhao WL; Cheng S
    Zhonghua Xue Ye Xue Za Zhi; 2017 Sep; 38(9):772-777. PubMed ID: 29081194
    [No Abstract]   [Full Text] [Related]  

  • 85. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.
    Ernst M; Oeser A; Besiroglu B; Caro-Valenzuela J; Abd El Aziz M; Monsef I; Borchmann P; Estcourt LJ; Skoetz N; Goldkuhle M
    Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013365. PubMed ID: 34515338
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Tumor necrosis at FDG-PET is an independent predictor of outcome in diffuse large B-cell lymphoma.
    Adams HJA; de Klerk JMH; Fijnheer R; Heggelman BGF; Dubois SV; Nievelstein RAJ; Kwee TC
    Eur J Radiol; 2016 Jan; 85(1):304-309. PubMed ID: 26515992
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Early risk stratification for diffuse large B-cell lymphoma integrating interim Deauville score and International Prognostic Index.
    Yim SK; Yhim HY; Han YH; Jeon SY; Lee NR; Song EK; Jeong HJ; Kim HS; Kwak JY
    Ann Hematol; 2019 Dec; 98(12):2739-2748. PubMed ID: 31712879
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Are dynamic or fixed FDG-PET measures of disease of greater prognostic value in patients with relapsed/refractory diffuse large B-cell lymphoma undergoing autologous haematopoietic stem cell transplantation?
    Campbell BA; Brown R; Lambertini A; Hofman MS; Bressel M; Seymour JF; Wirth A; MacManus M; Dickinson M
    Br J Haematol; 2023 May; 201(3):502-509. PubMed ID: 37015002
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Predictive value of baseline
    Zhu L; Meng Y; Guo L; Zhao H; Shi Y; Li S; Wang A; Zhang X; Shi J; Zhu J; Xu K
    Oncol Lett; 2021 Feb; 21(2):132. PubMed ID: 33552253
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Metabolic tumor volume from baseline [18 F]FDG PET/CT at diagnosis improves the IPI stratification in patients with diffuse large B-cell lymphoma.
    Zhang H; Xu Z; Zhou W; Chen J; Wei Y; Wu H; Wei X; Feng R
    Ann Hematol; 2024 Sep; ():. PubMed ID: 39222121
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Patient-reported outcomes provide prognostic information for survival in patients with diffuse large B-cell lymphoma: Analysis of 1239 patients from the GOYA study.
    Huang H; Datye A; Fan M; Knapp A; Nielsen T; Bottos A; Paulson JN; Trask PC; Efficace F
    Cancer Med; 2022 Sep; 11(17):3312-3322. PubMed ID: 35322932
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Comparison of Lugano Criteria Versus RECIL and PERCIST as Prognostic Factors in Diffuse Large B-Cell Lymphoma.
    Tang P; Cui F; Jiang C; Zhou Y; Su M; Tian R
    Clin Nucl Med; 2024 Apr; 49(4):308-311. PubMed ID: 38271234
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Generation and validation of a PET radiomics model that predicts survival in diffuse large B cell lymphoma treated with R-CHOP14: A SAKK 38/07 trial post-hoc analysis.
    Ceriani L; Milan L; Cascione L; Gritti G; Dalmasso F; Esposito F; Pirosa MC; Schär S; Bruno A; Dirnhofer S; Giovanella L; Hayoz S; Mamot C; Rambaldi A; Chauvie S; Zucca E
    Hematol Oncol; 2022 Feb; 40(1):11-21. PubMed ID: 34714558
    [TBL] [Abstract][Full Text] [Related]  

  • 94. CT-based versus FDG-PET/CT-based NCCN international prognostic index risk stratification in DLBCL.
    Adams HJ; de Klerk JM; Fijnheer R; Dubois SV; Nievelstein RA; Kwee TC
    J Natl Compr Canc Netw; 2015 Feb; 13(2):171-6. PubMed ID: 25691609
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Indicators describing the tumor lesion aggregation and dissemination and their impact on the prognosis of patients with diffuse large B cell lymphoma receiving chimeric antigen receptor T cell therapy.
    Dang X; Li P; Shen A; Lu Y; Zhu Z; Zhang M; Qian W; Liang A; Zhang W
    Cancer Med; 2024 Mar; 13(6):e6991. PubMed ID: 38506226
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Effect of second-line chemotherapy in treating relapsed or refractory diffuse large B cell lymphoma and prognosis analysis.
    Wang S; Bai Y
    J BUON; 2020; 25(4):2003-2010. PubMed ID: 33099945
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Chimeric antigen receptor T-cell therapy combined with autologous stem cell transplantation improved progression-free survival of relapsed or refractory diffuse large B-cell lymphoma patients: A single-center, retrospective, cohort study.
    Wang T; Xu L; Gao L; Tang G; Chen L; Chen J; Wang Y; Fu W; Yue W; Ye M; Yu J; Yu X; Feng D; Zhang A; Yang J
    Hematol Oncol; 2022 Oct; 40(4):637-644. PubMed ID: 35141937
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Prognostic significance of total metabolic tumor volume on
    Chang CC; Cho SF; Chuang YW; Lin CY; Chang SM; Hsu WL; Huang YF
    Oncotarget; 2017 Nov; 8(59):99587-99600. PubMed ID: 29245926
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Predictive value of [¹⁸F]fluoro-2-deoxy-D-glucose positron emission tomography for clinical outcome in patients with relapsed/refractory diffuse large B-cell lymphoma prior to and after autologous stem cell transplant.
    Qiao W; Zhao J; Xing Y; Wang C; Wang T
    Leuk Lymphoma; 2014 Feb; 55(2):276-82. PubMed ID: 23617323
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Diagnostic and prognostic value of baseline FDG PET/CT skeletal textural features in diffuse large B cell lymphoma.
    Aide N; Talbot M; Fruchart C; Damaj G; Lasnon C
    Eur J Nucl Med Mol Imaging; 2018 May; 45(5):699-711. PubMed ID: 29214417
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.